Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare pregnancy outcomes of frozen-thawed embryo transfer after endometrial preparation with vaginal estradiol or transdermal estradiol and to evaluate women's satisfaction
Frozen-thawed transfer embryo are more and more frequent but to date, there is no consensus on the ideal management of the adequate endometrial preparation.
Artificial preparation of endometrium is commonly used in assisted reproduction center because it is more easy to schedule.
Estradiol could be administrate by oral, vaginal or transdermal, but no protocol seems to improve clinical pregnancy rates.
To investigator's knowledge, transdermal estradiol has never been compare to vaginal administration before frozen-thawed embryo transfer.
Because transdermal administration could improve satisfaction of patients and reduce duration of treatment (when compare to oral administration), the investigators conduct a prospective study to compare clinical pregnancy rate after transdermal or vaginal estradiol administration to prepare the endometrium before frozen-thawed embryo transfer.
The investigator also evaluate side effects and patients satisfaction in both protocol.
The patients choose if they prefer vaginal or transdermal protocol after receiving sufficient information during medical consultation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| transdermal | transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks. |
| |
| vaginal | Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Estradiol 2 MG | Drug | Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| clinical pregnancy | defined as fetal cardiac activity at 12 weeks of gestation | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| chemical pregnancy | Defined as serum HCG levels >10 IU/L, 14 days after the embryo transfer, followed by a rapid decrease until being undetectable | 6 weeks |
| spontaneous pregnancy loss | Including early and late pregnancy losses |
Not provided
Inclusion Criteria:
Exclusion Criteria:
female
patients follow in our assisted reprodution unit, requesting frozen-thawed embryo transfer after ivf or icsi
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| BOUET Pierre-Emmanuel, MD | Contact | +33241353637 | pierreemmanuel.bouet@chu-angers.fr | |
| CORROENNE Romain | Contact | +33241353637 | corroenne.romain@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| BOUET Pierre Emmanuel | University Hospital, Angers | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Angers | Recruiting | Angers | 49100 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004958 | Estradiol |
| ID | Term |
|---|---|
| D004963 | Estrenes |
| D004962 | Estranes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Estradiol 100 µg | Drug | transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks. |
|
|
| 12 weeks |
| plasmatic estradiol concentration on the day of transfer | plasmatic estradiol concentration on the day of transfer | 21 days |
| plasmatic lh concentration on the day of transfer | plasmatic lh concentration on the day of transfer | 21 days |
| plasmatic progesterone concentration on the day of transfer | plasmatic progesterone concentration on the day of transfer | 21 days |
| endometrial thickness | sonographic measurement of endometrial thickness on the day of transfer | 21 days |
| annulation | defined when transfer is cancel if endometrial thickness is too thick (>6-7mm), when spontaneous ovulation is found with progesterone plasmatic increase and corpus luteum is seen by sonography or when unpredictable events occur (infections, ZIKA suspicion, endometriosis crisis, bad observance…). Annulation could be decided by biologist in case of embryo's lysis or bad quality seen after thawing. | 21 days |
| treatment duration | duration of treatment before transfer | 21 days |
| satisfaction evaluated by anonymous survey the day of transfer | evaluated by anonymous survey the day of transfer | 1 month |
| D011083 |
| Polycyclic Compounds |
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |